Auragens, a leader in stem cell research, development and treatment, has been asked to present its research alongside industry leaders such as NASA, SpaceX, Blue Origin and Axiom Space as a part of a larger, collaborative effort, to expand the capabilities of long term space exploration, at the ASCEND Conference in collaboration with American Institute of Aeronautics and Astronautics (AIAA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250408843612/en/

Dr. James Utley, Chief Scientific Officer, and Dr. Dan Briggs, President & CEO, of Auragens

The research and resulting paper are titled, “MSC-Based Biological Enhancement for Radiation Exposure: Leveraging MSC’s for Enhanced Radiation Resistance” and were created specifically to understand and then enable a human body to withstand the extended period it will require for a manned mission to Mars and a safe return. Authored by Auragens’ Chief Scientific Officer, Dr. James Utley, and Co-Authored by Auragens’ CEO, Dr. Dan Briggs, the opportunity to be a key component of an incredible opportunity to advance humanity made this an important focus of their research.

“Our genes carried us through Earth’s deepest freezes and have enabled our evolution, against all odds, and they are now yielding to us the capability to become interplanetary,” said Dr. Utley. He continued, “Thanks to the work at Auragens and our understanding of MCS’s, we may finally have the tools to actively shape this next evolutionary step.”

ASCEND (Accelerating Space Commerce, Exploration, and New Discovery) is an annual event organized by the AIAA, bringing together leaders from aerospace, science, and technology to advance the future of space exploration and industry. AIAA, the world’s largest aerospace technical society, plays a central role in shaping innovation and policy across the global space sector. Together, ASCEND and AIAA serve as a premier platform for groundbreaking collaborations, visionary thinking, and the commercialization of space.

“We approach our involvement with AIAA and ASCEND as both an honor and a responsibility,” said Auragens CEO Dr. Dan Briggs. “Through this collaboration, Auragens has made significant advancements in both our practical and our theoretical applications. Our learnings are already benefiting our patients of today while exponentially growing the possibilities for tomorrow.”

About Auragens – Auragens is a market leader in the field of stem cell treatments, research, and development. They operate their own laboratory onsite and are ISO certified while pursuing AABB accreditation and following all cGMP guidelines and FDA related regulations for safety. Treatments are provided at their private state-of-the-art facility in Panama City, Panama, which spans the entire 48^th floor of a Class A office building in the Beverly Hills of Panama City, known as Punta Pacifica. All science and medicine is overseen by a team of doctors hailing from universities such as Johns Hopkins, Stanford and Notre Dame among others. Published in numerous journals, Auragens is leading in cutting edge Regenerative Medicine with a goal of making their treatments a Standard of Care and available to all in need.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408843612/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.